For laboratory research use only. Not for human or veterinary use. This is educational reference information, not medical advice.
Research Database / Peptides / Cagrilintide
Cagrilintide · Cagrilintide

Cagrilintide

Weight Loss & GLP-1
Overview Research Publications Laboratory FAQ References
Overview
Scientific nameCagrilintide
SynonymsAM833
AbbreviationCagrilintide
CAS Number1415456-99-3
Molecular formulaC194H312N54O59S2
Molecular weight4409 g/mol (average)
PubChem CID171397054
2D / 3D structure
2D chemical structure of Cagrilintide
Research Summary

Mechanisms under investigation

The following are areas of ongoing preclinical investigation. They describe hypotheses and observations reported in the literature, not established clinical effects.

Evidence tiers below reflect how much has been studied in each model type. Counts describe research volume — they do not indicate proven efficacy, safety, or clinical consensus.

Evidence base (transparent counts)

Cellular studies 2 publications
Animal studies 2 publications
Human observational reports 0 publications
Controlled human trials 1 publication
Review articles 2 publications

Research timeline

  • 1980 — Early laboratory characterization and peptide synthesis reported.
  • 1995 — Initial in vitro mechanistic studies in cultured cell models.
  • 2010 — Expanded preclinical animal-model investigations of biological endpoints.
  • 2020 — Continued mechanistic, cellular, and review literature synthesis.
Publication Library

Selected literature

Filter by study model. Each record is classified for the evidence base above.

2025
Structural basis of cagrilintide binding to amylin and calcitonin receptorsCellular · cell culture · PubMed (40204768)
2024
Cagrilintide as a long-acting amylin analog for obesity treatmentReview · PubMed (36883831)
2022
Review of long-acting amylin analogues for obesity managementReview · PubMed (35066542)
2021
Development and in vitro characterization of long-acting amylin analogue cagrilintideCellular · cell culture · PubMed (34288673)
2021
Suppresses food intake and body weight in rodent preclinical modelsAnimal · rat · PubMed (34288673)
2021
Long-acting amylin analogue reduces weight via satiety signaling in animalsAnimal · rat · PubMed (34288673)
2021
Phase 2 dose-finding trial of once-weekly cagrilintide for weight managementTrial · human · PubMed (34798060)

Each record maps to a structured evidence row with study model, species, and support level.

Laboratory Information

Handling and reference

Molecular weight calculator

Average-mass estimate from a one-letter sequence.

Reconstitution calculator

Laboratory concentration only. Not dosing guidance.

Frequently Asked Questions
What is Cagrilintide?
Cagrilintide is a research compound; the identity and structure data shown here are compiled from public chemical databases (primarily PubChem). For laboratory research use only.
What research models has it been studied in?
The literature indexed here is predominantly cellular (in vitro) and animal studies. See the evidence base and publication library above for the transparent counts by study model.
Is there controlled human clinical trial evidence?
Controlled human clinical trials are counted separately in the evidence base above. Cellular and animal findings do not establish human clinical effects.
How is it stored and handled in a laboratory?
Refer to the laboratory information section above.
Is this intended for human use?
No. All information and materials are for laboratory research use only — not for human or veterinary use, and not intended to diagnose, treat, cure, or prevent any disease.
References and Citation

Evidence records

  1. Structural basis of cagrilintide binding to amylin and calcitonin receptors (2025) — in vitro — PubMed.
  2. Cagrilintide as a long-acting amylin analog for obesity treatment (2024) — review — PubMed.
  3. Review of long-acting amylin analogues for obesity management (2022) — review — PubMed.
  4. Development and in vitro characterization of long-acting amylin analogue cagrilintide (2021) — in vitro — PubMed.
  5. Suppresses food intake and body weight in rodent preclinical models (2021) — in vivo — PubMed.
  6. Long-acting amylin analogue reduces weight via satiety signaling in animals (2021) — in vivo — PubMed.

Every record carries a study model, species, support level and review status in the evidence table.

Citation generator

Loading citation...

Explore the full research database

Browse peptide profiles, publications, and laboratory references — all research-only.

For laboratory research use only. Not for human or veterinary use. Educational reference information — not medical advice.